Almac Doubles Global 2-8 °C Cold Room Capacity in Response to Increasing Biologics Demand
Almac has announced a significant investment to more than double the existing capacity of their 2–8 °C clinical supply labelling cold room facilities in the Group’s European and US-based facilities.
Additional dedicated temperature and humidity controlled labelling suites have been installed and are now live at Almac’s headquarter sites situated in Craigavon (UK), Souderton (PA) and Durham (NC) increasing their capacity to label temperature sensitive investigational products. This expansion represents the latest development in the company’s investment initiatives designed to meet growing client demand for specific services including a significant upsurge in clinical studies for biosimilar and biological investigational products.
The expansion of Almac’s cold room facilities adds significant capacity or clients requiring the development of valuable biologically sensitive investigational products, whilst complementing the company’s existing clinical supply chain management services.
Commenting on this latest expansion, Robert Dunlop, Managing Director of Almac’s Clinical Services Business Unit remarked: "We have witnessed significant growth in the biologics market in the past 12 months and this latest investment reflects both our on-going commitment to meeting the demands of the clinical trial market, as well as our ability to expand and adapt successfully to key developments within the pharmaceutical and biotech industries. These are exciting times for Almac as we continue to increase our range of services to deliver world class solutions to our global client base."
The cold room facilities expansion follows on from other recently announced investments including £54 million spent on the company’s pharmaceutical development and clinical services operations. This is in addition to the establishment of regional operations centres through strategic investments in Singapore and Japan geared towards meeting increasing customer demand in the Asia Pacific region.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance